Skip to main content
Clinical Trials/CTRI/2023/09/057974
CTRI/2023/09/057974CompletedPhase 2

A prospective, open-label, 4 arm study to evaluate the safety and efficacy of Skin care product for its non-comedogenic effect in healthy male or female volunteers - NI

Kreative Beauty Private Limited0 sites60 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
60

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1.Healthy Indian male/female healthy volunteers aged between 18-55 years.
  • 2.Willing to give Informed Consent Form.
  • 3.Mild to moderate Black heads on the face
  • 4.Willing to complete the study assessments/questionnaires.
  • 5.Willing to avoid usage of his/her own moisturizers and face
  • 6.serum for at least one week before Commencement and during this study.

Exclusion Criteria

  • 1.Pregnancy or breast feeding.
  • 2.Patients with pre-existing severe systemic disease necessitating long-term medication.
  • 3.Patients with mild to severe Anaphylaxis reactions.
  • 4.Evidence of significant uncontrolled co-morbid disease.
  • 5.Historyofcancer,includingsolidtumors,hematologic malignancies and carcinoma in situ
  • 6.Any neurological (congenital or acquired), vascular or systemic disorder which could affect any of the efficacy assessments.
  • 7.Participation in the current or previous clinical trial with any approved or investigational products during the past 1 month.

Investigators

Sponsor
Kreative Beauty Private Limited

Similar Trials

Active, not recruiting
Phase 1
Afatinib as second-line therapy for lung cancer with EGFR mutatioMetastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R)MedDRA version: 19.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-001077-14-PLBoehringer Ingelheim RCV GmbH & Co KG282
Active, not recruiting
Phase 1
Afatinib as second-line therapy for lung cancer with EGFR mutatioMetastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R)MedDRA version: 17.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-001077-14-ROBoehringer Ingelheim RCV GmbH & Co KG70
Completed
Phase 4
A Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants Receiving Emetogenic ChemotherapySymptomen en algemene pathologieChemotherapy-Induced Nausea and Vomiting
NL-OMON48224Merck Sharp & Dohme (MSD)6
Active, not recruiting
Phase 1
Three-day Fosaprepitant Regimen CINV Safety Study in Pediatric ParticipantsPrevention of Chemotherapy-Induced Nausea and Vomiting (CINV)MedDRA version: 21.1Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2018-004844-43-GRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
Active, not recruiting
Phase 1
Three-day Fosaprepitant Regimen CINV Safety Study in Pediatric ParticipantsPrevention of Chemotherapy-Induced Nausea and Vomiting (CINV)MedDRA version: 20.1Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2018-004844-43-NLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100